ModifiedPremera BluecrossPolicy N/A

Xolair (omalizumab) coverage and site-of-service criteria

Defines medical necessity, site-of-service review, indications, dosing limits, and documentation requirements for Xolair (omalizumab) for Premera members; applies to providers administering or requesting coverage for this drug.

Policy Summary

PayerPremera Bluecross

PolicyXolair (omalizumab) coverage and site-of-service criteria

Policy CodePolicy N/A

Change TypeMultiple substantive updates (authorization length, dosing, indications, exclusions)

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization confirming indication-specific criteria and updated authorization length of up to 12 months.

SourceLink

POLICY UPDATE CHANGES

Updated initial authorization length for all reviews from 6 months to 12 months.

Added prohibition on concurrent use of Xolair with Exdensur (depemokimab-ulaa) for asthma.

Updated chronic idiopathic urticaria dose limit to 600 mg every 2 weeks.

Updated asthma criteria to use maximum tolerated doses of inhaled corticosteroid rather than maximum doses; added FEV1/FVC <0.80 as an option.

Added treatment of certain individuals with IgE-mediated food allergies as an indication to criteria.

Updated CRSwNP criteria to require prior use of systemic corticosteroids in the last 2 years, contraindication to systemic corticosteroid therapy, or previous surgical removal of bilateral nasal polyps.

Added restrictions that Xolair is not to be used in combination with certain biologics for asthma and nasal polyps (e.g., Tezspire, Dupixent) and added Exdensur to the list of asthma-concurrent medications.

12 monthsinitial authorization length (all reviews)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Indications

Initial therapy — Moderate to severe persistent allergic asthma

Covered when ALL of the following are met for moderate to severe persistent allergic asthma:

Asthma initial criteria: Individual is aged 6 years or olderage >=6

Site-of-service review applies for ages >=13

Controller therapy: Is using maximum tolerated doses of an inhaled corticosteroid AND is using an inhaled long-acting beta-agonist (LABA)

Exacerbation or physiologic criteria (ONE of): One of: two or more asthma exacerbations in the previous 12 months requiring oral corticosteroids; OR one or more exacerbation requiring hospitalization, emergency department, or urgent care in the previous 12 months; OR FEV1 <80% predicted; OR FEV1/FVC <0.80; OR asthma worsens upon tapering of oral corticosteroid therapy

Allergy and laboratory criteria: Total serum IgE within 30–1,300 IU/mL for ages 6–12 OR 30–700 IU/mL for age >=12 AND positive skin test or RAST to a perennial aeroallergenIgE ranges as specified

Weight and dosing limits: Weight between 20 kg and 150 kg AND dose limited per prescribing information (dose table; maximum 750 mg every 4 weeks based on IgE and weight)weight 20–150 kg; dose ≤750 mg q4w

Initial therapy — Severe chronic idiopathic urticaria

Covered when ALL of the following are met for severe chronic idiopathic urticaria:

CIU patient and age: Individual is aged 12 years or older AND there is no evidence of an alternative cause of urticariaage >=12

Chronicity: Symptoms present for at least 6 weeks (chronic urticaria, itching, hives or angioedema)

Prior antihistamine therapy: Failed to respond to or intolerant of at least 2 H1-antihistamines at high doses (at least 2x normal, up to 4x) or maximum tolerated dose AND plans to continue low-dose H1 antihistamines

Concomitant therapy and exclusions: Xolair will not be used in combination with Dupixent (dupilumab) or Rhapsido (remibrutinib) for chronic urticaria

Initial therapy — CRSwNP

Covered when ALL of the following are met for CRSwNP maintenance therapy:

CRSwNP age and symptoms: Individual is aged 18 years or older AND has at least two of: facial pressure or pain; moderate to severe nasal congestion, discharge, or obstruction; or significant loss of smellage >=18

Objective findings and labs: Diagnosis of inadequately controlled bilateral CRSwNP confirmed by physical exam, sinus CT, or nasal endoscopy AND pretreatment total serum IgE >=30 IU/mL AND weight 30–150 kgIgE >=30 IU/mL; weight 30–150 kg

Prior therapy and combination therapy: Inadequate response or intolerance to intranasal corticosteroid monotherapy AND Xolair prescribed in combination with an intranasal corticosteroid AND has one of: prior use of systemic corticosteroids for nasal polyps in the last 2 years OR contraindication to systemic corticosteroids OR prior surgical removal of bilateral nasal polyps

Xolair will not be used in combination with specified biologics for this indication (e.g., Tezspire, Dupixent)

Initial therapy — IgE-mediated food allergy

Covered when ALL of the following are met for IgE-mediated food allergy:

Age and diagnosis: Individual is aged 1 year or older AND diagnosed with an IgE-mediated food allergy demonstrated by signs or symptoms of a significant systemic allergic reaction soon after known ingestion AND a positive skin prick test or positive serum food-specific IgEage >=1

Concomitant management: Xolair will be used in conjunction with an allergen-avoidant diet AND the individual has been prescribed an epinephrine auto-injector

Concomitant therapy exclusions: Xolair will not be used concomitantly with Palforzia (peanut allergen powder)

Dosing limits and prescriber: Dose limited to 600 mg every 2 weeks based on serum IgE and body weight per prescribing information; prescribed by or in consultation with an allergist, immunologist, or otolaryngologist

Not covered — Investigational uses

Not covered — Investigational

Investigational indications: Xolair is considered investigational for all other uses not listed in this policy, including but not limited to: allergic rhinitis, atopic dermatitis, other IgE-mediated allergic conditions not listed, latex allergy, bullous pemphigoid, and eosinophilic gastrointestinal disorders.

Indication-specific coverage criteria (trial-aligned)

Covered when patient meets trial-based indication criteria and has inadequate control on standard therapy

Asthma (trial-aligned): Patient (typically age ≥12 in pivotal trials) with moderate to severe allergic asthma inadequately controlled despite optimized inhaled corticosteroid therapy (usually with LABA and other controllers); positive perennial aeroallergen testing is typical; Xolair positioned as a last-line add-on based on trials showing 40–50% reduction in exacerbationsage >=12

Chronic Idiopathic Urticaria (trial-aligned): Patient with CIU meeting trial severity criteria (UAS7 ≥16 and weekly itch score ≥8) despite at least 2 weeks of H1 antihistamine therapy; trials showed efficacy at 150 mg and 300 mg regimens (75 mg not consistently effective)UAS7 >=16; weekly itch >=8

CRSwNP (trial-aligned): Patient with bilateral nasal polyps with NPS ≥5 (≥2 per nostril) and weekly average nasal congestion score >1 despite background nasal mometasone; trials used 24-week treatment durations

Coverage criteria by indication

Covered when indication-specific criteria and prior therapy requirements are met per FDA labeling and policy updates

Asthma (coverage rules): Member meets FDA indication for moderate to severe persistent asthma AND meets one or more exacerbation/physiologic criteria (two or more OCS-treated exacerbations in prior 12 months OR one or more exacerbation requiring hospitalization/ED/urgent care OR FEV1 <80% predicted OR dependence/worsening with oral corticosteroid taper) AND has had trials of maximum tolerated inhaled corticosteroid plus appropriate controllers; concurrent use with specified biologics (e.g., Tezspire, Dupixent, Exdensur) for same indication is prohibitedsee asthma exacerbation history

Chronic idiopathic/spontaneous urticaria (coverage rules): Member age ≥12 with CSU refractory to H1-antihistamines at appropriate doses; dosing limited to a maximum of 600 mg every 2 weeks; initial authorization length up to 12 months per policy600 mg q2w

CRSwNP (coverage rules): Member has inadequately controlled bilateral CRSwNP confirmed by exam, CT, or endoscopy; has two of specified symptoms; and meets one of: prior systemic corticosteroid use for nasal polyps in last 2 years OR contraindication to systemic corticosteroids OR prior bilateral nasal polypectomy; dosing per FDA label and not used concurrently with Dupixent for nasal polyps

Pediatric Asthma Dosing

Dosing for pediatric individuals (age 6 to <12) is determined by baseline total IgE and body weight according to the provided dose tables and using initial IgE for interruptions <1 year.

Pediatric dosing determination: Dose selection requires BOTH baseline total serum IgE and body weight mapped to the pediatric dosing table for ages 6 to <12; do not re-test IgE during active treatment (levels remain elevated); re-test only if treatment interruption ≥1 yearage 6 to <12; use initial IgE unless interruption >=1 year

Some weight/IgE combinations are specified as 'DO NOT DOSE' in the table; adjust dose for significant weight changes

Chronic Idiopathic Urticaria

Coverage for CIU follows fixed dosing and periodic reassessment.

CIU dosing and reassessment: Administer Xolair 150 mg or 300 mg subcutaneously every 4 weeks. Periodically reassess need for continued therapy. Initial authorization length updated to 12 months. Maximum CIU dose limit updated to 600 mg every 2 weeks.150 or 300 mg q4w; CIU dose limit 600 mg q2w

Dosing for CIU is independent of serum IgE or body weight

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Coverage for chronic rhinosinusitis with nasal polyps requires prior therapies and has combination-therapy exclusions.

CRSwNP prior therapy requirement: Individual must have inadequately controlled bilateral CRSwNP confirmed by exam, CT, or endoscopy AND meet ONE of: prior use of systemic corticosteroids to treat nasal polyps in the last 2 years OR contraindication to systemic corticosteroid therapy OR previous surgical removal of bilateral nasal polypsprior systemic corticosteroids in last 2 years OR contraindication OR prior bilateral polypectomy

Xolair will not be used in combination with tezepelumab; other biologic combination restrictions may apply

Combination Therapy Exclusions

Xolair must not be used concurrently with certain other biologic agents for the same indication.

Combination therapy exclusions: Do not use Xolair concurrently with Dupixent (dupilumab), Tezspire (tezepelumab), Exdensur (depemokimab-ulaa), or other listed biologics when those agents are being used for the treatment of the same condition (e.g., asthma or nasal polyps)

Policy lists specific agents and was updated to add Exdensur and to prohibit combinations with Tezspire and Dupixent in certain indications

Xolair (omalizumab) is considered investigational for all uses not listed in this policy. Examples of indications that are not covered include allergic rhinitis, atopic dermatitis, other IgE-mediated allergic conditions not listed in this document, latex allergy, bullous pemphigoid, and eosinophilic gastrointestinal disorders.

Clinical trials for chronic idiopathic urticaria evaluated Xolair at 75 mg, 150 mg, and 300 mg administered subcutaneously every 4 weeks. Trial results demonstrated consistent efficacy with the 150 mg and 300 mg doses, while the 75 mg dose did not demonstrate consistent evidence of efficacy and is not approved.

Xolair must not be used concurrently with other biologic agents when indicated for the same condition. Policy updates explicitly prohibit concurrent use with agents such as Tezspire (tezepelumab) for asthma and Dupixent (dupilumab) for nasal polyps; the prohibited list has been expanded to include additional agents per recent updates.

For pediatric asthma dosing (ages 6 to <12 years), dose selection is determined by baseline total serum IgE and body weight using the policy dosing tables. Certain large calculated weight/IgE combinations in the pediatric dose matrix are designated as DO NOT DOSE, indicating that Xolair should not be administered for those specific weight and IgE parameter combinations.

The policy reiterates combination-therapy restrictions across indications. In addition to previously listed agents, Xolair is not to be used in combination with specified biologics for asthma and nasal polyps (examples include Tezspire, Dupixent), and the list has been expanded in recent updates to include other agents (see policy history for details). These combination prohibitions also reference newer agents added to the list in the 2026 update.

Site-of-service review applies to Xolair administration. Hospital-based outpatient infusion or hospital outpatient clinical settings are not medically necessary for administration when the policy's site-of-service criteria are not met; medically necessary site-of-service criteria include clinical risks such as unstable renal function, difficult vascular access, acute mental status changes, or prior severe drug reactions/anaphylaxis that necessitate monitored administration.

Use of Xolair outside the populations specified in this policy (for example, in individuals who are not inadequately controlled despite optimized standard therapy) may be considered not medically necessary. The policy positions Xolair as a later-line agent for patients who remain uncontrolled despite appropriate inhaled corticosteroid–based regimens and other standard controllers.

Requests for Xolair to treat conditions outside FDA-labeled indications or without meeting the policy's specified criteria (for example, use for mild asthma or without required prior therapy or exacerbation history) are not supported by the policy and therefore do not meet medical necessity.

The policy repeatedly states that concurrent use of Xolair with specified biologic therapies for the same indication is not allowed. Examples cited in the policy include Tezspire (tezepelumab), Dupixent (dupilumab), and other agents that have been added to the prohibited list in recent updates; concurrent biologic therapy for the same condition is considered non‑supported by this policy.

Billing, Codes, and Dosing Thresholds

HCPCS CodesHCPCS

J2357

Injection, omalizumab (Xolair), 5 mg

No codes listed in this sectionmixed

No codes listed

Covered HCPCS CodesHCPCSCovered

J2357

Omalizumab, 1 mg

inv-24: IgE laboratory thresholds — age- and indication-specific total serum IgE entry ranges for dosing

Asthma (ages 6 to <12)Total serum IgE 30–1300 IU/mL required for dose determination per pediatric dosing tables; map baseline IgE and body weight to the pediatric dose table.

Asthma (>=12 years)Total serum IgE 30–700 IU/mL required for dose determination for adolescents/adults per prescribing information.

CRSwNP pretreatment IgEPretreatment total serum IgE ≥30 IU/mL required for CRSwNP eligibility.

Food allergy dosing referenceDosing for IgE‑mediated food allergy is limited and determined by serum IgE and body weight according to the most recent prescribing information (dose limits apply).

inv-25: Weight limits for dosing — weight ranges and dosing caps per prescribing information

Prior Authorization, Documentation, and Operational Rules

Prior Authorization

Prior Authorization Required

Prior authorization is required for Xolair (omalizumab) for all indications managed under this policy. Approvals may be issued for up to 12 months for initial reviews and re-authorizations when medical necessity criteria are met and documentation shows continued clinical benefit.

Initial and re-authorization approvals: up to 12 months
Requests must follow FDA dosing and administration (IgE/weight tables) where applicable
Pharmacy and medical benefit management: drug may be managed under either benefit

Prior Authorization

Authorization Depends on FDA IgE / Weight Dosing Table

Authorization decisions depend on dosing that matches the product's FDA-prescribing IgE and body-weight dosing tables for asthma (pediatric and adult) and the approved dosing regimens for other indications (e.g., CIU, CRSwNP). Non-adherence to the dosing table (IgE range, body weight limits, dosing frequency) may affect approval.

Asthma dosing must follow serum total IgE and body weight per FDA tables (adult/adolescent and pediatric tables)

Background and Clinical Rationale

Xolair (omalizumab) is a recombinant humanized monoclonal antibody that targets circulating IgE. It is used as an add‑on therapy to reduce allergic responses and is indicated for conditions including moderate-to-severe allergic asthma, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis with nasal polyps, and to reduce IgE‑mediated reactions in certain food allergy contexts as reflected in the policy.

Definitions and Scoring

inv-50: IgE-mediated food allergy — definition/key term

DefinitionIgE-mediated food allergy refers to clinical allergic reactions mediated by Immunoglobulin E (IgE) antibodies to one or more foods, demonstrated by signs/symptoms of a systemic allergic reaction soon after ingestion and positive skin prick or serum IgE testing.

Policy age thresholdPolicy coverage criteria specify consideration for individuals aged 1 year and older for IgE-mediated food allergy treatment with Xolair.

Concomitant therapy restrictionsXolair for food allergy must be used with an allergen‑avoidant diet, will not be used concomitantly with Palforzia, and the individual must have an epinephrine auto-injector prescribed.

inv-51: CRSwNP — definition/key term

DefinitionChronic rhinosinusitis with nasal polyps (CRSwNP) is inadequately controlled bilateral nasal polyposis confirmed by exam, sinus CT, or nasal endoscopy with associated symptoms such as facial pressure/pain, moderate to severe nasal congestion/obstruction or drainage, or significant loss of smell.

Policy Revision History

2026-05-01policy_updateLatest

Initial authorization length for all reviews was changed from 6 months to 12 months (reference to non-formulary exception reviews removed).

2026-02-01policy_update

CRSwNP criteria revised to require prior use of systemic corticosteroids in the last 2 years, contraindication to systemic corticosteroids, or prior bilateral nasal polypectomy; combination therapy restrictions updated for nasal polyps and CIU.

2026-02-01

Policy Summary

PayerPremera Bluecross

PolicyXolair (omalizumab) coverage and site-of-service criteria

Policy CodePolicy N/A

Change TypeMultiple substantive updates (authorization length, dosing, indications, exclusions)

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization confirming indication-specific criteria and updated authorization length of up to 12 months.

SourceLink

On This Page

inv-27: Asthma exacerbation history — exacerbation definitions used for eligibility (oral corticosteroid/hospitalization counts)

Exacerbation counts (oral corticosteroids)Two or more asthma exacerbations in the previous 12 months requiring use of oral corticosteroids meets the policy exacerbation criterion for eligibility.

Exacerbation requiring higher-level careOne or more exacerbation requiring hospitalization, emergency department visit, or urgent care in the previous 12 months also meets the criterion.

Alternate physiologic/exacerbation criteriaAlternatives include FEV1 <80% predicted or FEV1/FVC <0.80, or asthma that worsens upon tapering oral corticosteroids per updated criteria.

inv-28: Pediatric dosing weight/IgE thresholds — pediatric dosing table rules and IgE re-testing conditions

Pediatric dose determination (age 6 to <12)Dose selection requires both baseline total serum IgE and body weight mapped to the pediatric dosing tables; follow the tableed mg doses and dosing frequency (every 2 or 4 weeks).

Do not re-test IgE during treatmentTotal IgE remains elevated during treatment and for up to one year after discontinuation; do not re-test for dose determination during active treatment or interruptions <1 year — use initial IgE.

IgE re-test after long interruptionRe-test total serum IgE for dose determination only if treatment was interrupted for one year or more.

Denial Risk

Site-of-Service Denials Possible

Site-of-service limitations: hospital-based outpatient infusion settings and outpatient hospital IV infusion departments are considered not medically necessary for infusion/injectable therapy when site-of-service criteria are not met. Some administrations may require site-of-service review; outpatient administration is typical for Xolair but hospital outpatient setting may be denied if criteria are unmet.

Site considered medically necessary only for specified unstable clinical conditions (e.g., unstable renal function, difficult vascular access, severe prior anaphylaxis, grade 3–4 CRS requiring inpatient admission)
Routine outpatient administration in hospital-based infusion departments may be denied if site-of-service criteria are not met

Step Therapy

Last-line Therapy Positioning / Step Requirements

Xolair is positioned as a last-line or add-on therapy for asthma after optimization of standard controller therapies. Prior use of maximum tolerated inhaled corticosteroid plus a long-acting beta-agonist (LABA) and other appropriate controller therapies is required before approval.

Require trial and inadequate response to maximum tolerated inhaled corticosteroid and LABA (or equivalent optimized controller regimen)
Other controller agents (leukotriene modifiers, theophylline) should be considered/documented as appropriate prior therapy

Denial Risk

Denial Risk if Concurrent/Disallowed Therapies or Prior Therapy Criteria Not Met

Denial risk exists if requested therapy is to be used concurrently with listed disallowed biologics for the same indication or if prior-therapy and documentation requirements are not met.

Do not use concurrently with specific agents for asthma or CRSwNP when listed as incompatible (e.g., Exdensur, tezepelumab, dupilumab as specified in the policy updates)
Requests lacking required prior therapies (e.g., systemic corticosteroids or previous bilateral polypectomy for CRSwNP when required) may be denied
Concurrent use with disallowed therapies for an indication is denial trigger

Documentation Required

Required Clinical Documentation

Documentation submitted must support FDA dosing and administration, prior therapies, and exacerbation history; missing or insufficient documentation may lead to denial or request for additional information.

Include office visit notes with diagnosis, history, physical exam, and medication history
Provide evidence of prior controller therapy optimization (e.g., inhaled corticosteroid dose and LABA), oral/systemic steroid courses, surgeries (if applicable), or intolerance/contraindication to required therapies
For asthma: document exacerbation frequency, ER/urgent care visits, hospitalizations, FEV1 or FEV1/FVC where applicable
For CRSwNP: document pretreatment IgE, bilateral CRSwNP confirmation (exam, CT, or endoscopy), prior systemic corticosteroid use in last 2 years or contraindication or prior bilateral polypectomy

Billing Rule

Operational Rules and Benefit Application

Additional operational notes: Xolair requires administration in a healthcare setting for the first at least three doses before consideration of self-administration. The drug may be managed under the pharmacy and/or medical benefit and non-formulary exception references were removed; approvals follow the same 12-month authorization maximum.

At least 3 in-office administrations prior to self-administration determination
Managed through pharmacy and medical benefits — verify benefit routing at time of request
Non-formulary exception language removed; standard authorization process applies

Note

Appendix — Comparator and Prior Therapy Drug Lists

Appendix reference: provide lists of comparator and prior therapy drug classes (inhaled corticosteroids, long-acting bronchodilators, leukotriene modifiers, H1/H2 antihistamines, combination ICS/LABA products, oral corticosteroids) to support prior therapy requirements and step positioning.

Appendix lists inhaled corticosteroids (e.g., fluticasone, budesonide, mometasone, ciclesonide, beclomethasone)
Long-acting bronchodilators (e.g., salmeterol), combination ICS/LABA agents (Advair, Breo, Dulera, Symbicort)
Leukotriene modifiers (montelukast, zafirlukast), H1 antihistamines, H2 antihistamines, and oral corticosteroids

inv-52: Xolair (omalizumab) description — recombinant humanized anti-IgE monoclonal antibody produced in CHO cells

Agent descriptionXolair (omalizumab) is a recombinant, humanized anti-IgE monoclonal antibody produced in Chinese hamster ovary (CHO) cell suspension culture; it binds circulating IgE and inhibits IgE binding to high-affinity FcεRI receptors on mast cells and basophils.

Molecular/production detailsThe antibody is a humanized construct derived from a murine monoclonal (MaE11), with an approximate molecular weight of 149 kDa and produced in CHO cells in nutrient medium containing gentamicin.

inv-55: Moderate to severe persistent asthma — definition/term details

Term definitionModerate to severe persistent asthma describes individuals (policy references) aged ≥12 in some contexts or ≥6 for pediatric dosing who remain uncontrolled on inhaled corticosteroids (maximum tolerated) plus other controllers; trials required evidence of perennial aeroallergen sensitivity and reductions in exacerbations with omalizumab.

Physiologic and exacerbation criteriaPolicy lists qualifying criteria including repeated exacerbations, hospitalizations, FEV1 <80% predicted, or FEV1/FVC <0.80, or asthma worsens on tapering oral corticosteroids.